Source:http://linkedlifedata.com/resource/pubmed/id/15120331
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2004-5-3
|
pubmed:abstractText |
We have developed a therapeutic approach to wound repair involving immobilization of gene transfer vectors within biocompatible matrices (gene-activated matrix, or GAM). The matrix also serves as a scaffold for cellular in-growth and subsequent gene uptake and expression. An adenoviral vector encoding human platelet-derived growth factor-B delivered in collagen (AdPDGF-B/GAM) has demonstrated efficacy in models of wound repair. The safety, biodistribution, and immunogenicity profiles of AdPDGF-B/GAM were examined using a rabbit dermal wound model. Four weekly doses at 1 x 10(10) and 1 x 10(11) viral particles/cm2 of wound surface stimulated dose-related increases in granulation tissue formation and cell proliferation. In situ hybridization and immunostaining demonstrated concordant expression of human PDGF-B mRNA and protein. No treatment-related changes in hematology, serum chemistry, or histopathology were observed. Although AdPDGF-B DNA and PDGF-B mRNA were detected in wounds and axillary lymph nodes of treated animals, no AdPDGF-B was detected in blood or other organs. No immunologic responses against collagen were observed; however, as expected, IgG responses to AdPDGF-B and human PDGF-BB protein were detected. In adenovirus-preimmunized rats, attenuation of the wound healing response was modest (approximately 16%). Collectively, these observations indicate that repeat doses of AdPDGF-B/GAM are well tolerated and lead to robust, localized tissue repair.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
1525-0016
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
9
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
699-711
|
pubmed:dateRevised |
2006-4-21
|
pubmed:meshHeading |
pubmed-meshheading:15120331-Adenoviridae,
pubmed-meshheading:15120331-Animals,
pubmed-meshheading:15120331-Antibody Formation,
pubmed-meshheading:15120331-Collagen,
pubmed-meshheading:15120331-Disease Models, Animal,
pubmed-meshheading:15120331-Gene Expression,
pubmed-meshheading:15120331-Gene Therapy,
pubmed-meshheading:15120331-Genetic Vectors,
pubmed-meshheading:15120331-Granulation Tissue,
pubmed-meshheading:15120331-Lymph Nodes,
pubmed-meshheading:15120331-Polymerase Chain Reaction,
pubmed-meshheading:15120331-Polyvinyl Alcohol,
pubmed-meshheading:15120331-Proto-Oncogene Proteins c-sis,
pubmed-meshheading:15120331-RNA, Messenger,
pubmed-meshheading:15120331-Rabbits,
pubmed-meshheading:15120331-Skin,
pubmed-meshheading:15120331-Wound Healing
|
pubmed:year |
2004
|
pubmed:articleTitle |
Adenovirus encoding human platelet-derived growth factor-B delivered in collagen exhibits safety, biodistribution, and immunogenicity profiles favorable for clinical use.
|
pubmed:affiliation |
Selective Genetics, Inc., San Diego, CA 92121, USA.
|
pubmed:publicationType |
Journal Article
|